DE69123784D1 - Benzimidazolderivate, Verfahren zu deren Herstellung und Anwendung - Google Patents

Benzimidazolderivate, Verfahren zu deren Herstellung und Anwendung

Info

Publication number
DE69123784D1
DE69123784D1 DE69123784T DE69123784T DE69123784D1 DE 69123784 D1 DE69123784 D1 DE 69123784D1 DE 69123784 T DE69123784 T DE 69123784T DE 69123784 T DE69123784 T DE 69123784T DE 69123784 D1 DE69123784 D1 DE 69123784D1
Authority
DE
Germany
Prior art keywords
anion
benzimidazole
substd
opt
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69123784T
Other languages
English (en)
Other versions
DE69123784T2 (de
Inventor
Takehiko Naka
Kohei Nishikawa
Takeshi Kato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27526589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69123784(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of DE69123784D1 publication Critical patent/DE69123784D1/de
Publication of DE69123784T2 publication Critical patent/DE69123784T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Steroid Compounds (AREA)
DE69123784T 1990-04-27 1991-04-19 Benzimidazolderivate, Verfahren zu deren Herstellung und Anwendung Expired - Lifetime DE69123784T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP11314890 1990-04-27
JP14194290 1990-05-30
JP20866290 1990-08-06
JP26457990 1990-10-01
JP41367990 1990-12-24

Publications (2)

Publication Number Publication Date
DE69123784D1 true DE69123784D1 (de) 1997-02-06
DE69123784T2 DE69123784T2 (de) 1997-04-17

Family

ID=27526589

Family Applications (3)

Application Number Title Priority Date Filing Date
DE1998175004 Active DE19875004I2 (de) 1990-04-27 1991-04-19 Benzimidazolderivate Verfahren zu deren Herstellung und Anwendung
DE69123784T Expired - Lifetime DE69123784T2 (de) 1990-04-27 1991-04-19 Benzimidazolderivate, Verfahren zu deren Herstellung und Anwendung
DE69133149T Expired - Lifetime DE69133149T2 (de) 1990-04-27 1991-04-19 Benzimidazolderivate, ihre Herstellung und Verwendung als Angiotensin II-Antagonisten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE1998175004 Active DE19875004I2 (de) 1990-04-27 1991-04-19 Benzimidazolderivate Verfahren zu deren Herstellung und Anwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69133149T Expired - Lifetime DE69133149T2 (de) 1990-04-27 1991-04-19 Benzimidazolderivate, ihre Herstellung und Verwendung als Angiotensin II-Antagonisten

Country Status (21)

Country Link
US (4) US5196444A (de)
EP (2) EP0459136B1 (de)
JP (2) JP2514282B2 (de)
KR (1) KR100200541B1 (de)
CN (2) CN1048486C (de)
AT (2) ATE146779T1 (de)
CA (2) CA2040955C (de)
CY (1) CY2150B1 (de)
DE (3) DE19875004I2 (de)
DK (2) DK0720982T3 (de)
ES (2) ES2095266T3 (de)
FI (2) FI108434B (de)
GR (1) GR3022172T3 (de)
HU (2) HU213266B (de)
IE (1) IE911317A1 (de)
LU (1) LU90224I2 (de)
LV (1) LV10258B (de)
NL (1) NL970044I2 (de)
NO (3) NO300923B1 (de)
NZ (1) NZ237949A (de)
PT (1) PT97451B (de)

Families Citing this family (230)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332744A (en) * 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
US5223499A (en) * 1989-05-30 1993-06-29 Merck & Co., Inc. 6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists
IE70593B1 (en) * 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
DE4036706A1 (de) * 1990-11-17 1992-05-21 Hoechst Ag Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
GB9027208D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027198D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
FR2673427B1 (fr) * 1991-03-01 1993-06-18 Sanofi Elf Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
TW274551B (de) * 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
GB9201789D0 (en) * 1992-01-28 1992-03-11 Fujisawa Pharmaceutical Co Heterocyclic derivatives
US5354759A (en) * 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
JP2682353B2 (ja) * 1991-11-20 1997-11-26 武田薬品工業株式会社 経口用医薬組成物およびその製造法
TW284688B (de) 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
DE4203872A1 (de) * 1992-02-11 1993-08-12 Thomae Gmbh Dr K Imidazo(1,2-a)pyridine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1993018030A1 (en) * 1992-03-03 1993-09-16 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives as angiotensin ii antagonists
US5310929A (en) * 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
US5266583A (en) * 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
DK154092D0 (da) * 1992-12-23 1992-12-23 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
CA2115985A1 (en) * 1993-02-25 1994-08-26 Kohei Nishikawa Vascular hypertrophy suppressor
JP2787539B2 (ja) * 1993-02-26 1998-08-20 松森　　昭 ウイルス性疾患の予防または治療剤
JP3810020B2 (ja) * 1993-04-22 2006-08-16 武田薬品工業株式会社 腎疾患の予防または治療剤
JP2003306432A (ja) * 1993-04-22 2003-10-28 Takeda Chem Ind Ltd 腎疾患の予防または治療剤
US5721263A (en) 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
JP3057471B2 (ja) * 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
CZ154994A3 (en) * 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
US5391566A (en) * 1993-07-20 1995-02-21 Merck & Co., Inc. Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives
ZA945190B (en) * 1993-07-30 1995-02-24 Kotobuki Seiyaku Co Ltd Carboxymethylidenecycloheptimidazole derivatives method or manufacturing the same and therapeutic agents containing these compounds
US5824696A (en) * 1993-09-01 1998-10-20 Smithkline Beecham Corporation Medicaments
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
DE69517832T2 (de) * 1994-01-28 2000-11-09 Takeda Chemical Industries, Ltd. Ein Verfahren zur Herstellung von Tetrazolyl-Verbindungen
DE4408497A1 (de) * 1994-03-14 1995-09-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP1110551B1 (de) * 1994-03-16 2004-05-12 Sankyo Company Limited Okulares Hypotonikum
AU677702B2 (en) * 1994-10-13 1997-05-01 Takeda Pharmaceutical Company Limited A prophylactic or therapeutic drug for renal diseases
SE9501881D0 (sv) * 1995-05-19 1995-05-19 Astra Ab New pharmacological use of AII-receptor antagonists
SE9502219D0 (sv) * 1995-06-19 1995-06-19 Astra Ab Novel medical use
MY119312A (en) * 1995-10-06 2005-05-31 Novartis Ag At 1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
IL124969A (en) * 1995-12-28 2002-09-12 Fujisawa Pharmaceutical Co History of benzimidazole, processes for their preparation and pharmaceutical preparations containing them
ATE230263T1 (de) 1996-02-29 2003-01-15 Novartis Erfind Verwalt Gmbh At1 rezeptor antagonist zur anregung von apoptosis
SI0914158T2 (sl) * 1996-04-05 2006-04-30 Takeda Chemical Industries Ltd Farmacevtska kombinacija, ki vsebuje spojino z angiotenzin II-antagonisticno aktivnostjo in spojino, ki povecuje inzulinsko obcutljivost
CZ299162B6 (cs) * 1996-07-15 2008-05-07 Sankyo Company, Limited Farmaceutický prípravek a souprava
US5771604A (en) * 1997-04-07 1998-06-30 Maytag Corporation Clothes dryer air inlet arrangement
US6177587B1 (en) * 1997-05-26 2001-01-23 Takeda Chemical Industries, Ltd. Production method of aminobenzene compound
TW453999B (en) 1997-06-27 2001-09-11 Fujisawa Pharmaceutical Co Benzimidazole derivatives
EP1776954A3 (de) 1997-10-17 2009-11-11 Ark Therapeutics Limited Verwendung von Hemmern des Renin-Angiotensinsystems zur Behandlung von Schlaganfällen
WO1999042451A1 (en) * 1998-02-23 1999-08-26 Kureha Chemical Industry Co., Ltd. Benzimidazole derivative
DE19820151A1 (de) * 1998-05-06 1999-11-11 Hexal Ag Transdermales therapeutisches System zur Anwendung von Candesartan
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
HRP20010030A2 (en) 1998-07-15 2001-12-31 Teijin Ltd Thiobenzimidazole derivatives
RU2271809C2 (ru) 1998-12-23 2006-03-20 Новартис Аг Применение антагониста рецептора at-1 или модулятора рецептора ат-2 для лечения болезней, связанных с увеличением содержания рецепторов ат-1 или ат-2
US6465502B1 (en) 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
WO2000048634A1 (fr) * 1999-02-19 2000-08-24 Takeda Chemical Industries, Ltd. Preparations d'adsorption percutanee de compose ayant un antagonisme de recepteur d'angiotensine ii
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
US6972287B1 (en) 1999-06-10 2005-12-06 Pfizer Inc. Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
EA004632B1 (ru) * 1999-06-10 2004-06-24 Уорнер-Ламберт Компани Ингибиторы агрегации амилоидных белков, их применение (варианты), композиция на их основе и способ визуализации амилоидных отложений
JP2001089393A (ja) * 1999-07-21 2001-04-03 Takeda Chem Ind Ltd 脳血管障害の再発予防剤および脳血管障害の後遺症の改善・進展抑制剤
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
IL148127A0 (en) * 1999-08-30 2002-09-12 Aventis Pharma Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
WO2001060362A1 (fr) * 2000-02-18 2001-08-23 Takeda Chemical Industries, Ltd. INHIBITEURS DE TNF-$g(a)
SE0002353D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New use
DE60132702T2 (de) * 2000-08-11 2009-03-19 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Heterozyklische verbindungen als inhibitoren von tyrosin-kinasen
PE20020617A1 (es) 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
EP1314425A4 (de) * 2000-08-30 2004-06-02 Sankyo Co Medizinische zusammenstellung zur prophylaxe und behandlung von herzversagen
US20040102502A1 (en) * 2000-10-25 2004-05-27 Toshifumi Watanabe Preventing/remedies for portal hypertension
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
WO2002043709A1 (fr) 2000-12-01 2002-06-06 Takeda Chemical Industries, Ltd. Procede de production d'une preparation contenant une substance bioactive
WO2003014112A1 (en) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Crystal and process for producing the same
CN1589154A (zh) * 2001-08-28 2005-03-02 三共株式会社 含有血管紧张肽ii受体拮抗剂的药用组合物
US7107198B2 (en) * 2001-11-02 2006-09-12 Sun Microsystems, Inc. Automatic generation of reduced-size circuit models including inductive interaction
CA2466659A1 (en) 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Anticancer agents
DE10205335A1 (de) * 2002-02-07 2003-08-21 Bdd Group Holding Ag Zug Deuterierte biphenylsubstituierte Benzimidazole sowie diese Verbindungen enthaltende Arzneimittel
EP1482896A4 (de) * 2002-03-01 2005-11-23 Merck & Co Inc Aminoalkylphosphonate und verwandte verbindungen als edg-rezeptor-agonisten
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
ATE502635T1 (de) 2002-08-19 2011-04-15 Pfizer Kombinationstherapie gegen hyperproliferative erkrankungen
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
ATE393764T1 (de) * 2003-03-17 2008-05-15 Teva Pharma Polymorphe formen von valsartan
AU2003230193A1 (en) * 2003-03-27 2004-10-18 Hetero Drugs Limited Novel crystalline forms of candesartan cilexetil
SE0300988D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
EP1556363A2 (de) 2003-04-21 2005-07-27 Teva Pharmaceutical Industries Limited Verfahren zur herstellung von valsartan und zwischenprodukte davon
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
GB0316546D0 (en) * 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
US20060287537A1 (en) * 2003-08-27 2006-12-21 Stanislav Radl Method of removing the triphenylmethane protecting group
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005030202A1 (en) * 2003-09-26 2005-04-07 Novartis Ag Use of angiotensin ii receptor antagonists for treating cerebrovascular disorders
ES2284068T3 (es) * 2003-10-16 2007-11-01 Teva Pharmaceutical Industries Limited Preparacion de candesartan cilexetilo.
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
WO2005051298A2 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
WO2005051928A1 (en) * 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited Process for production of tetrazolyl compounds
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
JP2005206603A (ja) * 2004-01-21 2005-08-04 Teva Pharmaceutical Industries Ltd カンデサルタンシレキセチルの調製
GB0402262D0 (en) 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
EP1713795A2 (de) * 2004-02-11 2006-10-25 Teva Pharmaceutical Industries Ltd. Candesartan-cilexetil-polymorphe
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
NZ586285A (en) 2004-03-17 2011-12-22 Novartis Ag Use of aliskiren in monotherapy for treating diabetes and metabolic disorder (syndrome X)
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
KR100908308B1 (ko) * 2004-05-05 2009-07-17 테바 파마슈티컬 인더스트리즈 리미티드 순도가 높은 칸데사르탄 실렉세틸의 제조
JP2005330277A (ja) * 2004-05-19 2005-12-02 Teva Pharmaceutical Industries Ltd カンデサルタンシレキセチル多形体
JP2009185060A (ja) * 2004-05-19 2009-08-20 Teva Pharmaceutical Industries Ltd カンデサルタンシレキセチル多形体
US7588779B2 (en) * 2004-05-28 2009-09-15 Andrx Labs, Llc Pharmaceutical formulation containing a biguanide and an angiotensin antagonist
WO2005123720A1 (en) * 2004-06-18 2005-12-29 Ranbaxy Laboratories Limited Fine particles of the angiotensin ii antagonist candesartan cilexetil and process for production thereof
CN101044127A (zh) 2004-08-23 2007-09-26 惠氏公司 用作纤溶酶原激活剂抑制剂－1的噻唑基－萘基酸
KR20070055563A (ko) 2004-08-23 2007-05-30 와이어쓰 혈전증 및 심혈관 질병의 치료에 유용한 플라스미노겐활성화제 억제제 타입-1(ｐａｉ-1)의 조절제로서의옥사졸로-나프틸 산
MX2007002177A (es) 2004-08-23 2007-04-02 Wyeth Corp Acidos de pirrolo-naftilo como inhibidores de pai-1.
KR20070101843A (ko) 2004-10-08 2007-10-17 노파르티스 아게 확장기 기능장애 또는 확장기 심부전의 예방 또는 치료를위한 레닌 억제제의 용도
CA2585623C (en) 2004-10-27 2012-06-05 Daiichi Sankyo Company Limited Ortho-substituted benzene derivatives
US8022086B2 (en) * 2004-10-29 2011-09-20 Kowa Co., Ltd. Therapeutic agent for glomerular disease
EP1655298A1 (de) * 2004-11-03 2006-05-10 LEK Pharmaceuticals d.d. Krystalline Polymorpheme Formen von Candesartan Cilexetil
WO2006050922A1 (en) 2004-11-11 2006-05-18 Lek Pharmaceuticals D.D. Process for the synthesis of tetrazoles
AP2007003979A0 (en) * 2004-11-23 2007-06-30 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia
DE102004060699A1 (de) * 2004-12-16 2006-06-22 Ratiopharm Gmbh Verfahren zur Herstellung von Candesartan
WO2006067215A2 (en) * 2004-12-22 2006-06-29 Algry Química, S. L. Intermediate compounds for the preparation of angiotensin ii receptor antagonists
EP1835890A2 (de) * 2005-01-06 2007-09-26 Elan Pharma International Limited Candesartan-nanopartikelformulierungen
US20060194858A1 (en) * 2005-01-14 2006-08-31 Omer Malachi Preparation of crude candesartan cilexetil
WO2006079496A1 (en) * 2005-01-26 2006-08-03 Lek Pharmaceuticals D.D. New pharmaceutical composition containing candesartan cilexetil as lipophilic crystalline substance
DK1863801T3 (da) * 2005-03-30 2010-11-15 Takeda Pharmaceutical Benzimidazolderivat og anvendelse deraf
TW200719896A (en) * 2005-04-18 2007-06-01 Astrazeneca Ab Combination product
CN100400536C (zh) * 2005-04-30 2008-07-09 重庆圣华曦药业有限公司 坎地沙坦酯c-型晶体的制备方法
WO2006122254A2 (en) * 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Stable micronized candesartan cilexetil and methods for preparing thereof
WO2007074399A2 (en) 2005-06-06 2007-07-05 Medichem, S.A. Process for the preparation of tetrazolyl compounds
ES2264641B1 (es) * 2005-06-17 2008-03-01 Quimica Sintetica, S.A. Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios.
CA2615007A1 (en) 2005-07-13 2007-01-18 F. Hoffmann-La Roche Ag Benzimidazole derivatives as 5-ht6,5-ht24
SI22127A (sl) * 2005-10-07 2007-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek za pripravo kandesartan cileksetila
CZ299265B6 (cs) * 2005-10-20 2008-05-28 Zentiva, A. S. Zpusob výroby 1-(cyklohexyloxykarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)bifenyl-4-yl]methyl]benzimidazol-7-karboxylátu (candesartan cilexetilu)
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CN100344625C (zh) * 2005-12-22 2007-10-24 浙江天宇药业有限公司 一种制备坎地沙坦的方法
US7943780B2 (en) * 2006-02-15 2011-05-17 Matrix Laboratories Ltd. Process for the preparation of candesartan cilexetil
CN101024643A (zh) 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 咪唑－5－羧酸类衍生物、制备方法及其应用
WO2008035360A2 (en) * 2006-06-13 2008-03-27 Alembic Limited Novel crystalline forms of candesartan cilexetil, candesartan, tritylated candesartan and tritylated candesartan cilexetil
EA200900068A1 (ru) * 2006-07-28 2009-06-30 Крка, Товарна Здравил, Д. Д., Ново Место Способ получения формы i кандесартана цилексетила
GEP20125420B (en) 2006-08-10 2012-03-26 Takeda Pharmaceutical Solid pharmaceutical composition comprising benzimidazole compound
CA2665226C (en) 2006-10-05 2014-05-13 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP1908469A1 (de) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II Rezeptor Antagonisten zur Behandlung von systemischen Krankheiten bei Katzen
US8143435B2 (en) * 2006-10-10 2012-03-27 Mylan Laboratories Ltd. One pot process for the preparation of candesartan
EP2486910A3 (de) 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Vorrichtung mit mehreren Kammern und Dispenser
ES2315141B1 (es) * 2006-11-23 2009-12-22 Quimica Sintetica, S.A Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
EP2103610B1 (de) * 2006-12-06 2011-09-21 Shanghai Allist Pharmaceutical., Inc. Salze von imidazol-5-carbonsäure-derivaten, herstellungsverfahren und verwendung davon
CN101214242A (zh) 2007-01-05 2008-07-09 上海艾力斯医药科技有限公司 新的药用组合物
EP1952806A1 (de) 2007-02-01 2008-08-06 Helm AG Herstellungsverfahren für Candesartan-Adsorbate
TW200838501A (en) * 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
EP1988091B1 (de) 2007-02-07 2015-06-10 Kyowa Hakko Kirin Co., Ltd. Trizyklische verbindungen
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
EA200901140A1 (ru) 2007-03-01 2010-04-30 Пробиодруг Аг Новое применение ингибиторов глутаминилциклазы
ES2351542T3 (es) * 2007-03-08 2011-02-07 Teva Pharmaceutical Industries Ltd. Composición farmacéutica que comprende candesartan cilexetilo.
PE20130210A1 (es) * 2007-03-28 2013-03-11 Takeda Pharmaceutical Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph
EP2142514B1 (de) 2007-04-18 2014-12-24 Probiodrug AG Thioharnstoffderivate als glutaminylcyclaseinhibitoren
SI22488A (sl) * 2007-04-24 2008-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalni 1-(cikloheksiloksikarboniloksi)etil 1-((2'-cianobifenil-4-il)metil) - 2-etoksi-1h-benz(d)imidazol -7-karboksilat in proces za njegovo pripravo
TWI448284B (zh) * 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
JP5139515B2 (ja) 2007-04-25 2013-02-06 テバ ファーマシューティカル インダストリーズ リミティド 医薬賦形剤複合体
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
DK2170930T3 (da) 2007-06-04 2012-11-05 Synergy Pharmaceuticals Inc Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
TWI406850B (zh) 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
WO2009007986A1 (en) * 2007-07-11 2009-01-15 Alembic Limited An improved process for the preparation of candesartan cilexetil
WO2009035543A1 (en) 2007-09-07 2009-03-19 Theravance, Inc. Dual-acting antihypertensive agents
ES2385773T3 (es) 2007-12-11 2012-07-31 Theravance, Inc. Derivados de benzoimidazol, de doble acción, y su utilización como agentes antihipertensivos
CA2716367C (en) 2008-02-20 2015-05-26 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
US7989484B2 (en) 2008-04-29 2011-08-02 Theravance, Inc. Dual-acting antihypertensive agents
EP2328910B1 (de) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
WO2009157001A2 (en) * 2008-06-24 2009-12-30 Hetero Research Foundation Process for preparation of candesartan cilexetil
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US7863309B2 (en) 2008-07-24 2011-01-04 Theravance, Inc. Dual-acting antihypertensive agents
CN101648918B (zh) * 2008-08-15 2013-01-09 联化科技股份有限公司 坎地沙坦酯的中间体化合物及其合成方法
ES2377552T3 (es) 2008-09-17 2012-03-28 Helm Ag Composiciones disueltas fácilmente y estables de candesartán cilexetilo preparadas con una granulación por vía húmeda
US20100093701A1 (en) * 2008-10-10 2010-04-15 Bruce Damiano Combination therapy comprising angiotensin receptor blockers and vasopressin receptor antagonists
KR100995755B1 (ko) 2008-10-31 2010-11-19 일동제약주식회사 트리틸 칸데사르탄 실렉세틸의 개선된 제조방법
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
US9387249B2 (en) 2008-12-23 2016-07-12 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
JP5833000B2 (ja) 2009-07-07 2015-12-16 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 二重に作用するピラゾール抗高血圧症薬
ES2441419T3 (es) 2009-07-22 2014-02-04 Theravance, Inc. Agentes antihipertensivos de doble acción basados en oxazol
CN102695546B (zh) 2009-09-11 2014-09-10 前体生物药物股份公司 作为谷氨酰胺酰环化酶抑制剂的杂环衍生物
WO2011080684A1 (en) 2009-12-31 2011-07-07 Ranbaxy Laboratories Limited Process for the preparation of candesartan cilexetil
US8481549B2 (en) * 2010-01-19 2013-07-09 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
WO2011092666A1 (en) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited An improved process for the preparation of candesartan cilexetil, polymorphic forms of n-trityl candesartan and their uses thereof
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
SG183229A1 (en) 2010-03-10 2012-09-27 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
EP2560953B1 (de) 2010-04-21 2016-01-06 Probiodrug AG Hemmer der glutaminylzyklase
CN101880241B (zh) * 2010-07-14 2013-04-17 浙江美诺华药物化学有限公司 一锅法制备2-(取代苯基)甲氨基-3-硝基苯甲酸甲酯的方法
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
KR101251741B1 (ko) * 2010-12-16 2013-04-05 동화약품주식회사 칸데사르탄실렉세틸의 개선된 제조방법
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
CN102198129B (zh) * 2011-03-22 2016-03-30 浙江华海药业股份有限公司 含有坎地沙坦酯和氢氯噻嗪的口服片剂
CN102206186A (zh) * 2011-04-18 2011-10-05 张家港市信谊化工有限公司 坎地沙坦环合物的制备方法
WO2013030725A1 (en) 2011-08-26 2013-03-07 Wockhardt Limited Methods for treating cardiovascular disorders
WO2013041944A1 (en) 2011-09-19 2013-03-28 Ranbaxy Laboratories Limited Process for the preparation of micronized candesartan cilexetil
JP5850697B2 (ja) * 2011-10-18 2016-02-03 株式会社トクヤマ カンデサルタンシレキセチルの製造方法
WO2013090196A1 (en) 2011-12-15 2013-06-20 Takeda Pharmaceuticals U.S.A., Inc. Combinations of azilsartan and chlorthalidone for treating hypertension black patients
CN102391254B (zh) * 2011-12-16 2013-03-13 珠海润都制药股份有限公司 一种坎地沙坦的制备方法
CN103304543A (zh) * 2012-03-12 2013-09-18 邓俐丽 一种坎地沙坦酯的制备方法
CN102633816A (zh) * 2012-03-30 2012-08-15 李莎 头孢西丁酯化前体药物化合物及口服制剂
EP3338776A1 (de) 2012-05-01 2018-06-27 Translatum Medicus Inc. Verfahren zur behandlung und diagnose von erblindenden augenerkrankungen
JP6231553B2 (ja) 2012-05-07 2017-11-15 バイエル ファーマ アクチエンゲゼルシャフト ニフェジピンおよびカンデサルタン・シレキセチルを含む医薬投与形を製造する方法
US20140134187A1 (en) 2012-06-25 2014-05-15 The Johns Hopkins University Therapeutic and diagnostic methods for autism spectrum disorders and other conditions
JP6218084B2 (ja) 2012-10-04 2017-10-25 国立研究開発法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
CN102952040A (zh) * 2012-11-20 2013-03-06 峨眉山天梁星制药有限公司 一种坎地沙坦酯中间体的硝基还原为氨基的方法
PL236001B1 (pl) 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9339542B2 (en) * 2013-04-16 2016-05-17 John L Couvaras Hypertension reducing composition
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
EP3025711B1 (de) 2013-07-23 2020-11-18 Daiichi Sankyo Company, Limited Medikament zur vorbeugung oder behandlung von hypertonie
CN104098550A (zh) * 2014-07-17 2014-10-15 浙江华海药业股份有限公司 一种精制三苯甲基坎地沙坦的方法
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
US20180155326A1 (en) * 2015-06-05 2018-06-07 Zhejiang Huahai Pharmaceutical Co., Ltd. Method for preparing trityl candesartan
CZ2015687A3 (cs) 2015-10-02 2017-04-12 Zentiva, K.S. Farmaceutická kompozice obsahující kombinaci kandesartanu, amlodipinu a hydrochlorthiazidu
EP3219309A1 (de) 2016-03-17 2017-09-20 K.H.S. Pharma Holding GmbH Pharmazeutische zusammensetzung mit fixdosierungskombination von amlodipin, candesartan cilexetil und hydrochlorothiazid zur behandlung von bluthochdruck
WO2017164208A1 (ja) 2016-03-24 2017-09-28 第一三共株式会社 腎疾患の治療のための医薬
CN106432201B (zh) * 2016-09-14 2019-04-23 威海迪素制药有限公司 一种坎地沙坦酯结晶的制备方法
PL3648761T3 (pl) 2017-07-07 2024-07-22 Boehringer Ingelheim Vetmedica Gmbh Telmisartan do profilaktyki lub leczenia nadciśnienia u kotów
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
AU2019252676A1 (en) 2018-04-11 2020-11-26 Ohio State Innovation Foundation Methods and compositions for sustained release microparticles for ocular drug delivery
US20220089526A1 (en) 2019-01-02 2022-03-24 Linhai Huanan Chemical Co., Ltd. Synthesis Method for Candesartan Cilexetil Intermediate
CN119060040A (zh) 2019-01-18 2024-12-03 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法
CN110514758A (zh) * 2019-08-21 2019-11-29 天地恒一制药股份有限公司 一种坎地沙坦酯有关物质的检测方法
JP7440939B2 (ja) * 2020-08-13 2024-02-29 南京海融医薬科技股▲フン▼有限公司 イブプロフェンエステル系プロドラッグ、医薬組成物、調製方法および使用
US11655220B2 (en) 2020-10-22 2023-05-23 Hetero Labs Limited Process for the preparation of angiotensin II receptor blockers
EP4052695A1 (de) 2021-03-05 2022-09-07 Midas Pharma GmbH Stabile orale pharmazeutische zusammensetzungen mit fester dosis und sofortiger freisetzung mit amlodipin, atorvastatin und candesartan cilexetil
WO2023285646A1 (en) 2021-07-15 2023-01-19 Adamed Pharma S.A A pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension
CN114149414B (zh) * 2021-12-23 2023-08-04 浙江永宁药业股份有限公司 一种利用微反应器连续流制备坎地沙坦的方法
EP4598528A1 (de) 2022-10-04 2025-08-13 Arsenil Zabirnyk Hemmung der verkalkung der aortenklappe
EP4374855A1 (de) 2022-11-22 2024-05-29 KRKA, D.D., Novo Mesto Pharmazeutische darreichungsform von candesartan und indapamid
TW202508455A (zh) 2023-05-24 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 包含一或多種sglt-2抑制劑及替米沙坦(telmisartan)之非人類哺乳動物之腎臟疾病及/或高血壓之組合治療及/或預防
WO2025125409A1 (en) 2023-12-15 2025-06-19 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526896A (en) * 1978-12-26 1985-07-02 Riker Laboratories, Inc. Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof
JPS5671073A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4775679A (en) * 1985-04-25 1988-10-04 Merck & Co., Inc. Certain heterocyclic-ethyl-2,3-dihydrobenzofurans useful as anti-inflammatory agents
US4812462A (en) * 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4820843A (en) * 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4764623A (en) * 1987-06-15 1988-08-16 American Home Products Corporation N-(1H-tetrazol-5-yl-alkylphenyl)polyfluoroalkanamides
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
DE3928177A1 (de) * 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0400835A1 (de) * 1989-05-15 1990-12-05 Merck & Co. Inc. Substituierte Benzimidazole als Angiotensin II-Hemmer
GB8911854D0 (en) * 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
IE70593B1 (en) * 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
US5250554A (en) * 1989-10-24 1993-10-05 Takeda Chemical Industries, Ltd. Benzimidazole derivatives useful as angiotensin II inhibitors
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof

Also Published As

Publication number Publication date
FI982761L (fi) 1998-12-21
FI114983B (fi) 2005-02-15
ES2181742T3 (es) 2003-03-01
US5328919A (en) 1994-07-12
NO970195D0 (no) 1997-01-16
DE69123784T2 (de) 1997-04-17
PT97451A (pt) 1992-01-31
CA2204290C (en) 2001-12-18
CN1048486C (zh) 2000-01-19
LV10258B (en) 1995-04-20
NZ237949A (en) 1995-07-26
FI108434B (fi) 2002-01-31
NO911586L (no) 1991-10-28
JP2853611B2 (ja) 1999-02-03
FI911936A0 (fi) 1991-04-22
HUT57736A (en) 1991-12-30
EP0459136B1 (de) 1996-12-27
JPH04364171A (ja) 1992-12-16
DE69133149D1 (de) 2002-12-19
DE19875004I2 (de) 2002-03-28
IE911317A1 (en) 1991-11-06
CA2040955A1 (en) 1991-10-28
DE69133149T2 (de) 2003-03-13
NO300923B1 (no) 1997-08-18
EP0459136A1 (de) 1991-12-04
EP0720982A1 (de) 1996-07-10
GR3022172T3 (en) 1997-03-31
ES2095266T3 (es) 1997-02-16
KR910018359A (ko) 1991-11-30
ATE146779T1 (de) 1997-01-15
HU213266B (en) 1997-04-28
HK1000803A1 (en) 1998-05-01
EP0720982B1 (de) 2002-11-13
NL970044I1 (nl) 1998-03-02
CA2204290A1 (en) 1991-10-28
JPH0899960A (ja) 1996-04-16
NO970195L (no) 1997-01-16
FI982761A0 (fi) 1998-12-21
US5401764A (en) 1995-03-28
CN1058966C (zh) 2000-11-29
NO1998018I1 (no) 1998-06-25
US5705517A (en) 1998-01-06
NL970044I2 (nl) 1998-06-02
NO302752B1 (no) 1998-04-20
NO911586D0 (no) 1991-04-22
AU647469B2 (en) 1994-03-24
DK0720982T3 (da) 2003-03-17
LV10258A (lv) 1994-10-20
JP2514282B2 (ja) 1996-07-10
CN1055927A (zh) 1991-11-06
HU911347D0 (en) 1991-10-28
CN1147515A (zh) 1997-04-16
DK0459136T3 (da) 1997-04-01
KR100200541B1 (ko) 1999-06-15
CY2150B1 (en) 2002-08-23
PT97451B (pt) 1997-01-31
HU210871A9 (en) 1995-08-28
FI911936A7 (fi) 1991-10-28
AU7533191A (en) 1991-11-21
CA2040955C (en) 1998-02-03
US5196444A (en) 1993-03-23
ATE227709T1 (de) 2002-11-15
LU90224I2 (fr) 1998-05-11

Similar Documents

Publication Publication Date Title
DE19875004I2 (de) Benzimidazolderivate Verfahren zu deren Herstellung und Anwendung
KR920006335A (ko) 안지오텐신 ⅱ수용체 길항제
DE10299029I1 (de) Benzimidazole diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
UA42669A (uk) Антагоністи ангіотензину ii, спосіб їх отримання (варіанти), проміжна сполука (варіанти), спосіб їх отримання та фармацевтична композиція
DE69329727D1 (de) Neue imidazol derivate, ihre herstellung und therapeutische verwendung
YU56492A (sh) Derivati hinuklidina
KR950704313A (ko) 5-아릴인돌 유도체 및 세로토닌(5-ht₁)작용물질로서의 그의 용도(5-arylindole derivatives and their use as serotonin(5-ht₁)agonists)
KR920008032A (ko) 인돌- 및 벤즈이미다졸-치환 이미다졸 및 벤즈이미다졸 유도체
KR930701415A (ko) 약학적으로 활성인 벤조퀴나졸린 화합물
DK152090D0 (da) Piperidylsubstituerede indolderivater
NZ309499A (en) Styryl benzimidazole derivatives useful as inhibitors of smooth muscle cell proliferation
ATE92062T1 (de) Heterocyclische guanidine als 5ht-3-antagonisten.
DE3577558D1 (de) 4-hydroxy-3-chinolincarbonsaeurederivate, 2-substituiert durch eine stickstoff enthaltende gruppe, ihre herstellung, ihre verwendung als arzneimittel, diese enthaltende zubereitungen und zwischenprodukte.
ATE141091T1 (de) Färbemittel für keratinische fasern, die 4- monoindolyl 1,2-naphthochinone enthalten, 4- monoindolyl 1,2-naphthochinone
ATE31925T1 (de) 2-(formylamino)-n-(1h-tetrazol-5-yl)benzamide.
ES465221A1 (es) Procedimiento para la preparacion de nuevos derivados de 4- ter-buti-3'-clorodifenilamina con actividad antihistaminica.
RU2007143054A (ru) Терапевтическое средство против кератоконъюнктивального расстройства

Legal Events

Date Code Title Description
8364 No opposition during term of opposition